PMID- 21086905
OWN - NLM
STAT- MEDLINE
DCOM- 20101215
LR  - 20161021
IS  - 1124-0490 (Print)
IS  - 1124-0490 (Linking)
VI  - 27
IP  - 1
DP  - 2010 Jul
TI  - C-reactive protein predicts response to infliximab in patients with chronic 
      sarcoidosis.
PG  - 49-56
AB  - BACKGROUND: This study assessed the value of C-reactive protein as a predictor of 
      disease severity and response to infliximab therapy in patients with chronic 
      pulmonary sarcoidosis. DESIGN: Sera were collected through week 52 from 138 
      patients with chronic pulmonary sarcoidosis who received placebo or infliximab in 
      a randomized, double-blind, placebo-controlled study. We evaluated the response 
      to therapy by baseline CRP using a dichotomous cutpoint (0.8 mg/dL) for the 
      change from baseline in percent-predicted forced vital capacity (FVC), Saint 
      George's Respiratory Questionnaire (SGRQ), 6-minute walk distance (6MWD), Borg's 
      CR10 dyspnea score, and Physician Organ Assessment (POA). RESULTS: CRP was 
      elevated in 36% of patients at baseline, and was significantly reduced by 
      infliximab by week 2. Among patients with elevated baseline CRP, 
      infliximab-treated patients improved significantly compared with placebo-treated 
      patients in percent-predicted FVC (+2.5 versus -2.6%), 6MWD (+8.0 versus -34.1), 
      Borg's CR10 dyspnea score (pre-6MWD -0.8 versus +0.9, post-6MWD -1.1 versus 
      +0.8), and POA (-3.1 versus -0.3). Patients with lower CRP levels at baseline did 
      not show significant differences between the placebo and infliximab groups in 
      most endpoints evaluated. CONCLUSIONS: In chronic sarcoidosis patients, elevated 
      CRP appears to identify a subset with more severe disease who may respond better 
      to treatment with infliximab.
FAU - Sweiss, N J
AU  - Sweiss NJ
AD  - University of Chicago, Chicago, IL, USA. nsweiss@medicine.bsd.uchicago.edu
FAU - Barnathan, E S
AU  - Barnathan ES
FAU - Lo, K
AU  - Lo K
FAU - Judson, M A
AU  - Judson MA
FAU - Baughman, R
AU  - Baughman R
CN  - T48 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00073437
PT  - Journal Article
PL  - Italy
TA  - Sarcoidosis Vasc Diffuse Lung Dis
JT  - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
JID - 9610928
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*metabolism
MH  - Chronic Disease
MH  - Clinical Trials, Phase II as Topic
MH  - Double-Blind Method
MH  - Dyspnea/drug therapy/immunology
MH  - Exercise Test
MH  - Exercise Tolerance
MH  - Female
MH  - Humans
MH  - Infliximab
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Retrospective Studies
MH  - Sarcoidosis, Pulmonary/*drug therapy/immunology/physiopathology
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States
MH  - Vital Capacity
MH  - Walking
EDAT- 2010/11/20 06:00
MHDA- 2010/12/16 06:00
CRDT- 2010/11/20 06:00
PHST- 2010/11/20 06:00 [entrez]
PHST- 2010/11/20 06:00 [pubmed]
PHST- 2010/12/16 06:00 [medline]
PST - ppublish
SO  - Sarcoidosis Vasc Diffuse Lung Dis. 2010 Jul;27(1):49-56.